Based on the key measurements obtained from Pyxis Oncology's financial statements, Pyxis Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Pyxis Oncology's Property Plant And Equipment Gross is comparatively stable compared to the past year. Accumulated Other Comprehensive Income is likely to gain to about 59.5 K in 2025, whereas Other Current Liabilities is likely to drop slightly above 10.1 M in 2025. Key indicators impacting Pyxis Oncology's financial strength include:
The essential information of the day-to-day investment outlook for Pyxis Oncology includes many different criteria found on its balance sheet. An individual investor should monitor Pyxis Oncology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pyxis Oncology.
Please note, the imprecision that can be found in Pyxis Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pyxis Oncology. Check Pyxis Oncology's Beneish M Score to see the likelihood of Pyxis Oncology's management manipulating its earnings.
Pyxis Oncology Stock Summary
Pyxis Oncology competes with Zura Bio, Elevation Oncology, Mereo BioPharma, PDS Biotechnology, and X4 Pharmaceuticals. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Pyxis Oncology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Pyxis Oncology's current stock value. Our valuation model uses many indicators to compare Pyxis Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pyxis Oncology competition to find correlations between indicators driving Pyxis Oncology's intrinsic value. More Info.
Pyxis Oncology is regarded fourth in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, Pyxis Oncology's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pyxis Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Pyxis Oncology Systematic Risk
Pyxis Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pyxis Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Pyxis Oncology correlated with the market. If Beta is less than 0 Pyxis Oncology generally moves in the opposite direction as compared to the market. If Pyxis Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pyxis Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pyxis Oncology is generally in the same direction as the market. If Beta > 1 Pyxis Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pyxis Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pyxis Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pyxis Oncology growth as a starting point in their analysis.
Pyxis Oncology February 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pyxis Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pyxis Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pyxis Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Pyxis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pyxis Oncology's daily price indicators and compare them against related drivers.
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.